NISA INVESTMENT ADVISORS, LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 177 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2018. The put-call ratio across all filers is 0.46 and the average weighting 0.1%.

Quarter-by-quarter ownership
NISA INVESTMENT ADVISORS, LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$2,852
-22.7%
800.0%0.00%
Q2 2023$3,690
+46025.0%
80
-61.9%
0.00%
Q1 2023$8
-20.0%
2100.0%0.00%
Q4 2022$10
-99.9%
2100.0%0.00%
Q3 2022$8,000
-98.4%
210
-97.5%
0.00%
-100.0%
Q2 2022$509,000
+1541.9%
8,533
+1870.7%
0.00%
Q1 2022$31,000
-75.8%
433
-76.3%
0.00%
-100.0%
Q4 2021$128,000
-16.9%
1,829
+7.5%
0.00%0.0%
Q3 2021$154,000
-57.2%
1,702
-54.9%
0.00%
-50.0%
Q2 2021$360,000
-39.5%
3,772
-27.8%
0.00%
-50.0%
Q1 2021$595,000
-17.7%
5,2220.0%0.00%
-20.0%
Q4 2020$723,000
+366.5%
5,222
+177.0%
0.01%
+400.0%
Q3 2020$155,000
+355.9%
1,885
+333.3%
0.00%
Q2 2020$34,000
+100.0%
435
+13.0%
0.00%
Q1 2020$17,000
+41.7%
385
+35.1%
0.00%
Q4 2019$12,0000.0%2850.0%0.00%
Q3 2019$12,000
-14.3%
285
+32.6%
0.00%
Q2 2019$14,000
-6.7%
2150.0%0.00%
Q1 2019$15,000
+66.7%
2150.0%0.00%
Q4 2018$9,000
-43.8%
2150.0%0.00%
Q3 2018$16,000
-23.8%
215
-21.8%
0.00%
Q2 2018$21,000
+133.3%
275
+57.1%
0.00%
Q1 2018$9,000
-50.0%
175
-35.2%
0.00%
Q1 2017$18,000
-48.6%
270
-46.0%
0.00%
Q4 2016$35,0000.0%5000.0%0.00%
Q3 2016$35,000
+133.3%
500
+66.7%
0.00%
Q2 2016$15,000
-21.1%
3000.0%0.00%
Q1 2016$19,0003000.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q3 2018
NameSharesValueWeighting ↓
Abingworth LLP 38,100$2,928,0001.67%
Opaleye Management Inc. 80,000$6,149,0001.59%
HIGHLINE CAPITAL MANAGEMENT, L.P. 410,000$31,517,0001.06%
Opus Point Partners Management, LLC 6,311$485,0001.05%
SECTOR GAMMA AS 68,015$5,228,0000.87%
Capital Impact Advisors, LLC 27,074$2,061,0000.76%
FORTALEZA ASSET MANAGEMENT INC/ 1,130$87,0000.71%
CAPITAL INTERNATIONAL LTD /CA/ 46,957$3,610,0000.63%
Virtus ETF Advisers LLC 8,794$676,0000.60%
Rock Springs Capital Management LP 200,000$15,374,0000.59%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders